Information Provided By: 
Fly News Breaks for August 10, 2017
ACHN
Aug 10, 2017 | 08:19 EDT
As reported previously, Baird analyst Brian Skorney downgraded Achillion to Neutral from Outperform. He said the PNH data reported earlier this week was better than expected but he is not convinced that given the drug's therapeutic window, dosing, and impact on LDH that it can be competitive with Soliris. Skorney maintained his $5 price target on Achillion shares.
News For ACHN From the Last 2 Days
There are no results for your query ACHN
